Spyre Therapeutics, Inc. (SYRE)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Spyre Therapeutics (SYRE) Files Annual Report to Shareholders
# 🔍 First, A Quick Reality Check Hello! I've got your request to summarize the SEC filing for Spyre Therapeutics (SYRE). However, the document text you provided is just a placeholder (`<PDF>` tag) with **no actual filing content** inside it. An ARS (Annual Report to Shareholders) is typically a co
SYRE Shareholders Vote on Directors Auditor and Stock Plan
# 🧾 What This Document Is This is a **DEF 14A**, also known as a **Proxy Statement**. Think of it as an invitation and instruction manual for a company's annual shareholder meeting. Spyre Therapeutics is asking its owners (the shareholders) to vote on several important company decisions. It outline
SEC filings
All filings →Insider trades
All insider trades →Spyre Therapeutics, Inc. has no reported insider trades in the last 90 days.